SSA
RLAY icon

Schonfeld Strategic Advisors’s Relay Therapeutics RLAY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,880
Closed -$715K – 2939
2026
Q1 		$715K Buy
71,880
+10,027
+16% +$89.7K 0.01% 1239
2025
Q4 		$523K Buy
+61,853
New +$441K ﹤0.01% 1378
2025
Q2 		– Sell
-204,055
Closed -$535K – 2456
2025
Q1 		$535K Sell
204,055
-150,445
-42% -$589K ﹤0.01% 1557
2024
Q4 		$1.46M Buy
+354,500
New +$1.93M 0.01% 966
2024
Q3 		– Sell
-105,518
Closed -$688K – 2358
2024
Q2 		$688K Buy
+105,518
New +$721K ﹤0.01% 1355
2023
Q1 		– Sell
-23,603
Closed -$353K – 2559
2022
Q4 		$353K Buy
23,603
+1,942
+9% +$37.2K ﹤0.01% 1719
2022
Q3 		$485K Buy
+21,661
New +$475K ﹤0.01% 1776
2020
Q4 		– Sell
-18,473
Closed -$787K – 1833
2020
Q3 		$787K Buy
+18,473
New +$704K 0.02% 772

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Schonfeld Strategic Advisors's RLAY Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 71,880 shares — an estimated $715K sold.

Schonfeld Strategic Advisors first reported a position in RLAY in Q3 2020 and held it in 8 quarters. The position peaked at $1.46M in Q4 2024. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 71,880 Relay Therapeutics shares in Q2 2026, an estimated $715K.
  • Schonfeld Strategic Advisors first reported a position in Relay Therapeutics in Q3 2020 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Relay Therapeutics position peaked at $1.46M in Q4 2024.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.